Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954347 | 1.00 | AR (1.00) | ARCYP2C19 | |
| SCHEMBL2958856 | 1.00 | AR (1.00) | ARCYP2C19 | |
| SCHEMBL13216169 | 1.00 | AR (1.00) | ARCYP2C19 | |
| SCHEMBL29361549 | 1.00 | AR (1.00) | ARCYP2C19 | |
| SCHEMBL13215941 | 1.00 | AR (1.00) | ARCYP2C19 | |
| SCHEMBL13199496 | 0.94 | AR (0.88) | ARCYP2C19 | |
| SCHEMBL13216333 | 0.94 | AR (0.88) | ARCYP2C19 | |
| SCHEMBL2958161 | 0.94 | AR (0.88) | ARCYP2C19 | |
| SCHEMBL13199495 | 0.94 | AR (0.88) | ARCYP2C19 | |
| SCHEMBL13216331 | 0.94 | AR (0.88) | ARCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200046734-A1 | Methods of Reducing Mammographic Breast Density and/or Breast Cancer Risk | HAVAH THERAPEUTICS PTY LTD (AU) | 2020-02-13 | — | — | US | claimed |
| US-10471073-B2 | Methods of reducing mammographic breast density and/or breast cancer risk | Havah Therapeutics Pty Ltd. (AU) | 2019-11-12 | — | — | US | claimed |
| WO-2016061135-A1 | DRUG COMBINATIONS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND METHODS OF MAKING AND USING THEM | VICUS THERAPEUTICS, LLC (US) | 2016-04-21 | — | — | WO | claimed |
| US-20140329809-A1 | NEW LEUKOCYTE INFILTRATE MARKERS FOR ROSACEA AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-11-06 | — | — | US | claimed |
| EP-2771484-A1 | NEW LEUKOCYTE INFILTRATE MARKERS FOR ROSACEA AND USES THEREOF | Galderma Research & Development (FR) | 2014-09-03 | — | — | EP | claimed |
| WO-2013060865-A1 | NEW LEUKOCYTE INFILTRATE MARKERS FOR ROSACEA AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-02 | — | — | WO | claimed |
| US-12383563-B2 | Methods of reducing mammographic breast density and/or breast cancer risk | Havah Therapeutics Pty Ltd. (AU) | 2025-08-12 | — | — | US | disclosed |
| US-20240358715-A1 | METHODS OF REDUCING MAMMOGRAPHIC BREAST DENSITY AND/OR BREAST CANCER RISK | Havah Therapeutics Pty Ltd. (AU) | 2024-10-31 | — | — | US | disclosed |
| US-11883414-B2 | Methods of reducing mammographic breast density and/or breast cancer risk | Havah Therapeutics Pty Ltd. (AU) | 2024-01-30 | — | — | US | disclosed |
| EP-3209301-B1 | METHODS OF REDUCING MAMMOGRAPHIC BREAST DENSITY AND/OR BREAST CANCER RISK | HAVAH THERAPEUTICS PTY LTD (AU) | 2023-06-07 | — | — | EP | disclosed |
| US-20220079954-A1 | Methods of Reducing Mammographic Breast Density and/or Breast Cancer Risk | Havah Therapeutics Pty Ltd. (AU) | 2022-03-17 | — | — | US | disclosed |
| CN-113633644-A | Method for reducing mammographic breast density and/or breast cancer risk | 哈瓦赫治疗有限公司 | 2021-11-12 | — | — | CN | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-7405234-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405234-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | AR 1/4885CYP2C19 396/4885 |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | AR 1/4885CYP2C19 396/4885 |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | AR, ESRRA, SHBG | AR 1/4885CYP2C19 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.